The classification of fibromyalgia syndrome

Müller, Wolfgang; Schneider, E. M.; Stratz, T

doi:10.1007/s00296-007-0403-9

Cited by 66 publications

(59 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nerve growth factor (NGF), which stimulates the production of substance P in small, afferent, unmyelinated neurons, was found to be elevated in the CSF of FMS patients with primary FMS, but not in FMS with an associated painful inflammatory condition (secondary FMS) (71). This finding addresses the clinical finding of subgroups in FMS (72)(73)(74). Elevated CSF substance P could be a common link between primary and secondary FMS, but the groups differ with regard to the mechanism responsible for the elevated substance P. In primary FMS, NGF seems to induce the elevated CSF substance P from central interneurons.…”

Section: Central Sensitizationsupporting

confidence: 81%

Etiopathogenetic mechanisms of fibromyalgia syndrome

Stisi

Cazzola²,

Buskila

et al. 2011

Reumatismo

View full text Add to dashboard Cite

Section: Central Sensitizationsupporting

confidence: 81%

Etiopathogenetic mechanisms of fibromyalgia syndrome

Stisi

Cazzola²,

Buskila

et al. 2011

Reumatismo

View full text Add to dashboard Cite

“…Turk et al, [8] considered FMS as a heterogeneous disorder and also classified patients into three groups based on psychosocial and behavioral characteristics. On the other hand, Müller et al, [9] recommended dividing patients into four groups according to the existence of pain, depression secondary to pain, depression with concomitant FMS, and somatoform disorder. The authors suggested treatment with 5-HT3 receptorblocking agents in the subgroup with high pain sensitivity, antidepressant therapy for the subgroup characterized by depression, and psychotherapy in the group with somatoform pain disorder.…”

mentioning

confidence: 99%

Ten Year Results of a Fibromyalgia Out-Patient Clinic: Is There a Happy Ending?

et al. 2011

View full text Add to dashboard Cite

Amaç: Bu geriye dönük özdeş grup çalışmasında, fibromiyalji sendromlu (FMS) hastaların klinik özellikleri, tedavi seçenekleri ve sonuçları belirlendi ve Fibromiyalji İzlem Polikliniğimizde (FİP) edinilen 10 yıllık deneyimlerin sonuçları sunuldu. Hastalar ve yöntemler: Fibromiyalji sendromu şüphesi ile FİP'ye sevk edilen 308 hastanın (247 kadın, 61 erkek) 252'sine FMS tanısı konuldu. Tüm hastaların demografik verileri kaydedildi. Fibromiyalji izlem polikliniği'nin hasta formları kullanılarak hastalarda yaygın vücut ağrısı, yorgunluk, uyku bozukluğu, sabah tutukluğu, parestezi, Raynaud fenomeni, göz kuruluğu, ağız kuruluğu, iritabl bağırsak sendromu, baş ağrısı, libido azalması, kadın üretral sendromu semptomları veya subjektif şişlik mevcut olup olmadığı sorgulandı. Üç veya altı aylık aralıklarla yapılan her görüşmenin sonunda ağrı şiddeti, uyku bozukluğu, hassas nokta sayısı, total miyaljik skor, fibromiyalji etki anketi (FEA), sağlık değerlendirme anketi (SDA) ve Beck depresyon envanteri (BDE) de kaydedildi. Kaydedilen tüm veriler eksik verileri dikkate alınarak analiz edildi. Bulgular: FMS (+) ve FMS (-) hastalar arasında hastalık süresi, hassas nokta sayısı, total miyaljik skor (p<0.001), BDE, baş ağrısı, parestezi, uyku bozuklukları, sabah tutukluğu, libido azalması ve iritabl bağırsak sendromu (p<0.05) açılarından istatistiksel olarak anlamlı farklılık saptandı. FMS (+) hastalarda, bir hafta boyunca uykuya dalma güçlüğü çekilen gün sayısı (uyku-1), total miyaljik skor, toplam FEA skoru ve toplam SDA skoru şeklindeki klinik parametreler açısından zaman içerisinde anlamlı değişiklikler görüldü. Giriş ve son kontrol arasında, selektif serotonin geri alım inhibitörü ilaç alan hastalarda total FEA skoru ve ağrıda anlamlı iyileşme görüldü (p<0.05). Amitriptilin tedavisi uygulanan FMS (+) hastalarda uyku-1'de anlamlı iyileşme görüldü, bununla birlikte sertralin ile klinik parametrelerde anlamlı farklılık saptanmadı. Sonuç: Fibromiyalji sendromu çok çeşitli klinik belirti ve semptomlarla seyreden bir kas-iskelet sistemi hastalığı oldundan, en uygun tedavinin uygulanabilmesi için her hastanın ağırlıklı klinik özelliğine göre değerlendirilmesi şarttır. Bu hastaları alt gruplara ayırmak yararlı olabilir.Anahtar sözcükler: Fibromiyalji sendromu; ilaç tedavisi; sondurum; retrospektif çalışma; alt grup. Objectives:In this retrospective cohort, we determined the clinical characteristics, treatment options and outcomes of fibromyalgia syndrome (FMS) patients and reported the results of the 10 years of experience of our Fibromyalgia Follow-up Outpatient Clinic (FOC). Patients and methods:Of the 308 patients (247 females, 61 males) who were referred to the FOC with suspicion of FMS, 252 were diagnosed with FMS. The demographic data of all patients were recorded. The patient forms of the FOC were used to question whether the patients had widespread body pain, fatigue, sleep disorders, morning stiffness, paresthesia, Raynaud's phenomenon, dry eye, dry mouth, irritable bowel syndrome, headaches, decreased libido, symptoms of fe...

show abstract

“…They were classified as primary FM patients (with no definitive organic factor triggering the syndrome) according to the classification criteria of Mu¨ller et al (group 1: FM with sensitivity to pain but no diagnosis of depression or other relevant psychiatric disorder). 21 Six HW (who had no pain disorders or infectious illness at the time of blood sampling) served as the control group (mean AE SD age 26 AE 2 yr). The same exclusion criteria were applied to the control group as to the FM volunteers.…”

Section: Study Design and Fm Patientsmentioning

confidence: 99%

Altered release of chemokines by phagocytes from fibromyalgia patients: a pilot study

2015

View full text Add to dashboard Cite

Fibromyalgia (FM) is a syndrome characterized by widespread chronic pain and is associated with elevated systemic inflammatory biomarkers, and an elevated innate cellular response. The aim of this study was to determine if fibromyalgia patients have altered ability to release pro-inflammatory chemokines by isolated neutrophils and monocytes. The study participants were women diagnosed with FM (n ¼ 6) and a control group of healthy women (HW) (n ¼ 6). Supernatant concentrations of eotaxin (CCL11), human macrophage-derived chemokine (MDC) (CCL22) and growth regulatedoncogene (GRO-a) (CXCL1) released by both monocytes and neutrophils either resting or stimulated by LPS were determined by ELISA and compared between the FM and HW groups. Both resting and activated monocytes from FM patients released more eotaxin, MDC and GRO-a than those from HW. However, there were no significant differences in the release of chemokines from neutrophils of FM patients and the ones from healthy women. In conclusion, monocytes from women with FM are deregulated, releasing higher amounts of eotaxin, MDC and GRO-a than healthy individuals. This fact does not occur in neutrophils from women with FM.

show abstract

The classification of fibromyalgia syndrome

Cited by 66 publications

References 24 publications

Etiopathogenetic mechanisms of fibromyalgia syndrome

Etiopathogenetic mechanisms of fibromyalgia syndrome

Ten Year Results of a Fibromyalgia Out-Patient Clinic: Is There a Happy Ending?

Altered release of chemokines by phagocytes from fibromyalgia patients: a pilot study

Contact Info

Product

Resources

About